Cue Biopharma, Inc. (CUE): who owns it and who trades it
As of Nov 16, 2026, CUE insiders reported 15 open-market sales worth $2.4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Shao-Lee Lin (CEO), with $1.9M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Cue Biopharma
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CUE
48 funds and institutions reported CUE shares worth $51.8M at the end of Q2 2026, about 2% of the company. The largest holder is Bleichroeder LP with 0.4%.
Funds and institutions (13F) 2%Everyone else 98%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Bleichroeder LP | 370,682 | 0.38% | $11.7M | – |
| Driehaus Capital Management LLC | 292,144 | 0.30% | $9.2M | – |
| Vanguard Capital Management LLC | 161,700 | 0.17% | $5.1M | – |
| Ikarian Capital, LLC | 104,364 | 0.11% | $3.3M | – |
| Tetragon Partners GP Ltd | 93,819 | 0.10% | $3M | – |
| Stempoint Capital LP | 66,995 | 0.07% | $2.1M | – |
| BlackRock, Inc. | 57,807 | 0.06% | $1.8M | – |
| ADAR1 Capital Management, LLC | 55,193 | 0.06% | $1.7M | – |
| Lion Point Capital, LP | 52,928 | 0.05% | $1.7M | – |
| Squadron Capital Management LLC | 50,000 | 0.05% | $1.6M | – |
| Diadema Partners LP | 48,369 | 0.05% | $1.5M | – |
| Geode Capital Management, LLC | 47,824 | 0.05% | $1.5M | – |
| Boothbay Fund Management, LLC | 31,459 | 0.03% | $993K | – |
| UBS Group AG | 26,700 | 0.03% | $843K | – |
| Citadel Advisors LLC | 25,633 | 0.03% | $809K | – |
| Vanguard Fiduciary Trust Co | 24,476 | 0.03% | $772K | – |
| Texas Capital Bank Wealth Management Services Inc | 22,881 | 0.02% | $722K | – |
| Renaissance Technologies LLC | 14,689 | 0.02% | $464K | – |
| Persistent Asset Partners Ltd | 12,332 | 0.01% | $389K | – |
| Robertson Stephens Wealth Management, LLC | 11,133 | 0.01% | $351K | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CUE insiders reported $0 of open-market purchases and $2.4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | Sumita Ray | Chief Legal Compliance O | Sale | 1,844 | $28.05 | $51.7K | Form 4 |
| Oct 12, 2026 | Shao-Lee Lin | CEO | Sale | 10,000 | $27.50 | $275K | Form 4 |
| Oct 12, 2026 | Shao-Lee Lin | CEO | Sale | 1,087 | $28.05 | $30.5K | Form 4 |
| Oct 12, 2026 | Michael Vincent Meluzio | Vice president | Sale | 1,144 | $28.05 | $32.1K | Form 4 |
| Aug 13, 2026 | Sumita Ray | Chief Legal Compliance O | Sale | 2,383 | $29.37 | $70K | Form 4 |
| Aug 13, 2026 | Sumita Ray | Chief Legal Compliance O | Sale | 6,442 | $30.35 | $196K | Form 4 |
| Aug 13, 2026 | Sumita Ray | Chief Legal Compliance O | Sale | 4 | $31.13 | $125 | Form 4 |
| Aug 13, 2026 | Michael Vincent Meluzio | Vice president | Sale | 3 | $31.13 | $93 | Form 4 |
| Aug 13, 2026 | Michael Vincent Meluzio | Vice president | Sale | 4,106 | $30.35 | $125K | Form 4 |
| Aug 13, 2026 | Michael Vincent Meluzio | Vice president | Sale | 1,519 | $29.37 | $44.6K | Form 4 |
| Aug 13, 2026 | Shao-Lee Lin | CEO | Sale | 5,423 | $27.19 | $147K | Form 4 |
| Aug 13, 2026 | Shao-Lee Lin | CEO | Sale | 10,460 | $29.48 | $308K | Form 4 |
| Aug 13, 2026 | Shao-Lee Lin | CEO | Sale | 2,375 | $28.11 | $66.8K | Form 4 |
| Aug 12, 2026 | Shao-Lee Lin | CEO | Sale | 34,225 | $26.99 | $924K | Form 4 |
| Aug 12, 2026 | Shao-Lee Lin | CEO | Sale | 5,775 | $27.75 | $160K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Shao-Lee Lin | Chief Executive Officer, Director | – | $1.9M | Oct 12, 2026 |
| Sumita Ray | Chief Legal Compliance Officer | – | $317K | Oct 12, 2026 |
| Michael Vincent Meluzio | VP, Prin. Accounting Officer | – | $201K | Oct 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CUE short interest
High short interest. 11.9% of CUE shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 238%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 862,798 CUE shares were sold short, 11.9% of the shares outstanding, up 8.9% from the report before. At the average daily volume of 113,963 shares, buying them all back would take about 7.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 862,798 | 11.88% | +9% | 113,963 | 7.6 |
| Oct 15, 2026 | 792,553 | 10.91% | +13% | 213,851 | 3.7 |
| Sep 30, 2026 | 702,198 | 9.67% | +111% | 666,076 | 1.1 |
| Sep 15, 2026 | 332,105 | 4.57% | +4% | 136,259 | 2.4 |
| Aug 31, 2026 | 318,420 | 4.38% | -3% | 180,671 | 1.8 |
| Aug 14, 2026 | 327,442 | 4.51% | -6% | 200,890 | 1.6 |
| Jul 31, 2026 | 349,876 | 0.36% | +14% | 184,644 | 1.9 |
| Jul 15, 2026 | 307,891 | 0.32% | +3% | 138,660 | 2.2 |
| Jun 30, 2026 | 298,077 | 0.31% | +8% | 111,200 | 2.7 |
| Jun 15, 2026 | 274,983 | 0.28% | -1% | 73,707 | 3.7 |
| May 29, 2026 | 277,694 | 0.28% | +9% | 107,168 | 2.6 |
| May 15, 2026 | 255,157 | 0.26% | -12% | 2.03M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Cue Biopharma company events
Cue Biopharma filed 17 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership). The latest was on Sep 21, 2026.
- Sep 21, 2026AnnouncementOf this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company is hosting a conference call and live webcast to discuss the clinical data on September 21, 2026 at 8:00 a.m. Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Aug 3, 2026LeadershipCue Biopharma, Inc. announced that the Company’s Board of Directors appointed James Ahlers as the Company’s Chief Financial Officer, effective as of July 30, 2026. Filing
- Jul 10, 2026LeadershipTo implement the Company’s 2026 Stock Incentive Plan and long-term incentive framework, both approved at the most recent shareholder meeting, the Company’s board of directors granted on July 9, 2026 an aggregate of 1,064,492 restricted stock units to its employees and executive officers as one-time… Filing
- Jun 3, 2026LeadershipAt the Special Meeting of Stockholders of Cue Biopharma, Inc. held on June 1, 2026, the Company’s stockholders approved the Cue Biopharma, Inc. 2026 Stock Incentive Plan, which had previously been adopted by the Board, subject to stockholder approval. Filing
- Jun 2, 2026LeadershipCue Biopharma, Inc. and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company and as members of the committees of the Board on which they… Filing
- May 1, 2026LeadershipThe Board adopted the Company’s 2026 Inducement Stock Incentive Plan, pursuant to which the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stock-based awards, and performance awards with respect to an aggregate of… Filing
- Apr 22, 2026SharesChanged the rights of its shareholders. Filing
- Apr 13, 2026VoteReported shareholder vote results. Filing
- Apr 7, 2026AnnouncementCue Biopharma, Inc. received notice from Boehringer Ingelheim that Boehringer Ingelheim had approved selection of its first compound for lead optimization under the Collaboration and License Agreement entered into with Boehringer Ingelheim on April 10, 2025 for the research, development and… Filing
- Mar 27, 2026LeadershipThe Board of Directors of Cue Biopharma, Inc. appointed Lucinda Warren, the Chief Financial and Business Officer of the Company, as Interim President and Chief Executive Officer, effective as of March 27, 2026. Filing
- Mar 16, 2026ResultsReleased financial results. Filing
- Feb 18, 2026AnnouncementCue Biopharma, Inc. has set April 13, 2026 as the date for the Company’s 2026 Annual Meeting of Stockholders. Filing
- Feb 12, 2026LeadershipThe Board of Directors of Cue Biopharma, Inc. appointed Lucinda Warren, the Chief Business Officer of the Company, as Chief Financial and Business Officer of the Company, effective February 9, 2026. Filing
- Dec 19, 2025AgreementCue Biopharma, Inc. entered into an underwriting agreement with H.C. Wainwright & Co., LLC, as representative of the several underwriters named therein, relating to an underwritten public offering of (i) 12,500,000 shares of the Company’s common stock, $0.001 par value per share, and accompanying… Filing
- Nov 24, 2025AnnouncementShared information with investors. Filing
- Nov 20, 2025LeadershipCue Biopharma, Inc. and Matteo Levisetti, Chief Medical Officer, agreed that Dr. Levisetti’s employment with the Company will terminate effective November 28, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Cue Biopharma financials
Famous investors that hold CUE
3 of the 50 well-known investors we track reported holding CUE in their latest 13F filing. The largest position is Israel Englander's, worth $1.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 44,356 | $1.1M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 19,808 | $512K | 0.0% | -23% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 10,289 | $266K | 0.0% | -30% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named CUE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G | 5.9% |
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G | 10.0% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G | 5.9% |
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G | 10.0% |
| Nov 16, 2026 | DRIEHAUS CAPITAL MANAGEMENT LLC | 13G/A | 4.0% |
| Nov 16, 2026 | DRIEHAUS CAPITAL MANAGEMENT LLC | 13G/A | 4.0% |
| Nov 10, 2026 | Bleichroeder LP | 13G/A | 8.8% |
| Nov 10, 2026 | Bleichroeder LP | 13G/A | 8.8% |
| Oct 8, 2026 | Mark E. Strome | 13G/A | 8.5% |
| Oct 8, 2026 | Mark E. Strome | 13G/A | 8.5% |
Questions about Cue Biopharma, Inc. (CUE) stock
Who owns the most CUE stock?
The largest reported owner of Cue Biopharma, Inc. (CUE) is Bleichroeder LP, with 0.4% of the company. In total, 48 funds and institutions reported holding CUE at the end of Q2 2026, together about 2% of the shares. See the largest owners.
Are CUE insiders buying or selling?
In the last 12 months, CUE insiders reported no open-market purchases and 15 sales worth $2.4M. The latest trade was on Oct 12, 2026. See every trade.
What is the short interest in CUE?
As of Oct 30, 2026, 862,798 CUE shares were sold short, 11.9% of the shares outstanding, up 8.9% from the report before. At the average daily volume of 113,963 shares, buying them all back would take about 7.6 trading days (days to cover). See the history.
Which famous investors hold CUE?
3 of the 50 well-known investors we track reported CUE in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $1.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.